News
Imagine treating a genetic disease not by managing symptoms for life, but by correcting the underlying genetic error itself. Inventors at NIH are advancing that vision with a gene editing technology designed to deliver highly precise genetic corrections, opening new possibilities for therapies that
Company Overview: AUTM is the nonprofit leader in efforts to educate, promote and inspire professionals – throughout their careers – to support the development of academic research that changes the world. AUTM’s community is comprised of more than 3,000 members who work in more than 800 universities
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored
Ellipsoid zone (EZ) loss has been proposed as evidence of progression of several retinal degenerative diseases, including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus